A detailed history of Smithfield Trust CO transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Smithfield Trust CO holds 129 shares of HALO stock, worth $6,811. This represents 0.0% of its overall portfolio holdings.

Number of Shares
129
Holding current value
$6,811
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $6,617 - $8,310
129 New
129 $7,000
Q1 2023

May 11, 2023

BUY
$32.86 - $55.7 $7,886 - $13,368
240 Added 28.92%
1,070 $40,000
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $33,249 - $49,335
830 New
830 $47,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.35B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Smithfield Trust CO Portfolio

Follow Smithfield Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Smithfield Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Smithfield Trust CO with notifications on news.